FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

Teresa Brevini, Mailis Maes, Gwilym J. Webb, +76

Nature

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide

Maddalena Cerrone, Omamah Alfarisi, Megan Neary, +7

Journal of Antimicrobial Chemotherapy

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis

Rajith K. R. Rajoli, Henry Pertinez, Usman Arshad, +20

British Journal of Clinical Pharmacology

The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine

Megan Neary, Mohammed Lamorde, Adeniyi Olagunju, +6

Clinical Pharmacology & Therapeutics

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals

Maddalena Cerrone, Xinzhu Wang, Megan Neary, +7

Clinical Infectious Diseases

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Mohammed Lamorde, Xinzhu Wang, Megan Neary, +8

Clinical Infectious Diseases

Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2

Katherine U. Gaynor, Marina Vaysburd, Maximilian A. J. Harman, +28

Nature Communications

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics

Usman Arshad, Henry Pertinez, Helen Box, +18

Potential Anti-sars-cov-2 DrugImmunologyEc 90PharmacotherapyAntiviral Drug +15

Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART

Megan Neary, Catherine A. Chappell, Kimberly K. Scarsi, +7

Journal of Antimicrobial Chemotherapy

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

Rajith K. R. Rajoli, Henry Pertinez, Usman Arshad, +20